The Biopharma Industry Outlook on 2024: Guarded Optimism for a Rebound

Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector. There are now some signs of a turnaround, from a rebounding market to a flurry of pharma company acquisitions. Surging demand for new obesity drugs has lifted Eli Lilly and Novo Nordisk, while catalyzing an industry-wide race to follow them. The Food and Drug Administration may soon approve a new Alzheimer’s drug. Antibody-drug conjugates and radiopharmaceuticals promise to offer new ways of treating certain cancers.

Read the full article: The Biopharma Industry Outlook on 2024: Guarded Optimism for a Rebound //

Source: https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2024/704572

Leave a Comment

Your email address will not be published.

Scroll to Top